Company · AZN
AstraZeneca
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
84
47 still marketed
Novel approvals
39
Approvals since 2021
82
Originals and new uses
Phase 3 trials
894
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Klygefa approved NovelOrphanNov 13, 2026
- Imfinzi new use Priority reviewNov 13, 2026
- Ultomiris new use Priority reviewOrphanOct 21, 2026
- Breztri Aerosphere approved Oct 8, 2026
- Truqap new use Sep 16, 2026
- Tagrisso new use OrphanSep 14, 2026
- Etcamah approved NovelSep 4, 2026
- Truqap new use Jun 12, 2026
- Imfinzi new use May 28, 2026
- Baxfendy approved NovelPriority reviewMay 15, 2026
Drugs in development (82)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- Savolitinibhmpl-504, AZD6094Phase 311 trials
AstraZeneca · Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- SurovatamigAZD0486, TNB-486Phase 39 trials
AstraZeneca · B-cell Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Untreated Follicular Lymphoma
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- AZD0780Phase 36 trials
AstraZeneca · Cardiovascular Disease, Dyslipidaemia, Heterozygous Familial Hypercholesterolaemia
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- CeralasertibAZD6738Phase 35 trials
AstraZeneca · Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer
- ALXN2220Phase 34 trials
AstraZeneca · Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Transthyretin Amyloid Cardiomyopathy, Amyloid Transthyretin Cardiomyopathy
- AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials
AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma
- BFFBFF MDI 320, BFF MDI 160Phase 34 trials
AstraZeneca · Asthma
- MonalizumabIPH2201Phase 34 trials
AstraZeneca · Non-small Cell Lung Cancer, Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck
- ALXN1850Phase 33 trials
AstraZeneca · Hypophosphatasia
- BGF MDI 320BGFPhase 33 trials
AstraZeneca · Asthma, COPD (Chronic Obstructive Pulmonary Disease)
- LHRHLuteinizing hormone-releasing hormone agonist, Luteinizing Hormone-Releasing Hormone AgonistsPhase 33 trials
AstraZeneca · ER-Positive HER2-Negative Breast Cancer, Ovarian Cancer
- Oteracil Potassiumgimeracil], S-1 [TegafurPhase 33 trials
AstraZeneca · Biliary Tract Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma, Malignant Neoplasms of Digestive Organs
Recruiting Phase 3 trials
Largest first.
- A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First EventPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07000357 · 15,100 participants (planned) · Start Jun 4, 2025 · Primary completion Oct 26, 2029
Drug: AZD0780; Placebo · For: Cardiovascular Disease
Sites: Athens, Alabama; Birmingham, Alabama; Fairhope, Alabama · 1,452 sites in all
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06677060 · 11,300 participants (planned) · Start Mar 14, 2025 · Primary completion Dec 17, 2029
Drug: Baxdrostat and dapagliflozin · For: Heart Failure
Sites: Birmingham, Alabama; Centreville, Alabama; Fairhope, Alabama · 977 sites in all
- A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07753993 · 7,000 participants (planned) · Start Aug 21, 2026 · Primary completion Oct 4, 2030
Drug: Elecoglipron; Placebo · For: Chronic Kidney Disease
Sites: Huntsville, Alabama; Montgomery, Alabama; Sheffield, Alabama · 715 sites in all
- A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07761117 · 6,950 participants (planned) · Start Aug 24, 2026 · Primary completion Sep 3, 2029
Drug: Elecoglipron; Placebo · For: Heart Failure With Preserved Ejection Fraction (HFpEF); Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Sites: Fairhope, Alabama; Anchorage, Alaska; Gilbert, Arizona · 679 sites in all
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06283966 · 5,250 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 3, 2027
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Athens, Alabama; Cullman, Alabama; Fairhope, Alabama · 922 sites in all
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressurePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06742723 · 5,000 participants (planned) · Start Mar 3, 2025 · Primary completion Dec 18, 2029
Drug: Baxdrostat/dapagliflozin; Placebo/dapagliflozin · For: Chronic Kidney Disease and Hypertension
Sites: Fairhope, Alabama; Sun City, Arizona; Tucson, Arizona · 771 sites in all
- A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07667803 · 4,500 participants (planned) · Start Jun 29, 2026 · Primary completion Jul 31, 2028
Drug: Elecoglipron; Placebo · For: Weight Management
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 325 sites in all
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05774951 · 4,300 participants (planned) · Start Mar 31, 2023 · Primary completion Apr 20, 2027
Drug: Camizestrant; Tamoxifen and 3 more · For: Breast Cancer, Early Breast Cancer
Sites: Birmingham, Alabama; Dothan, Alabama; Anchorage, Alaska · 709 sites in all
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05624450 · 3,527 participants (planned) · Start Dec 13, 2022 · Primary completion Nov 4, 2027
Drug: Tozorakimab; Placebo · For: Viral Lung Infection and Acute Respiratory Failure
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 473 sites in all
- A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07624305 · 2,800 participants (planned) · Start Sep 1, 2026 · Primary completion Jul 1, 2030
Drug: Balcinrenone/dapagliflozin; Dapagliflozin and 2 more · For: Renal Insufficiency, Chronic
Sites: Huntsville, Alabama; Surprise, Arizona; Tempe, Arizona · 478 sites in all
Marketed drugs (47)
Newest FDA action first.
- Klygefa Gefurulimab · 2026
- Imfinzi Durvalumab · 2017
- Symbicort Aerosphere Budesonide, Formoterol Fumarate · 2023
- Ultomiris Ravulizumab-Cwvz · 2018
- Soliris Eculizumab · 2007
- Breztri Aerosphere Budesonide, Formoterol Fumarate, Glycopyrrolate · 2026
- Crestor Rosuvastatin Calcium · 2003
- Truqap Capivasertib · 2023
- Tagrisso Osimertinib Mesylate · 2015
- Etcamah Camizestrant · 2026
- Imjudo Tremelimumab-Actl · 2022
- Xigduo Xr Dapagliflozin, Metformin Hydrochloride · 2014
- Saphnelo Anifrolumab-Fnia · 2021
- Farxiga Dapagliflozin · 2014
- Koselugo Selumetinib Sulfate · 2020
- Koselugo Selumetinib, Selumetinib Sulfate · 2025
- Baxfendy Baxdrostat · 2026
- Fasenra Benralizumab · 2017
- Brilinta Ticagrelor · 2011
- Breztri Aerosphere Budesonide, Formoterol Fumarate, Glycopyrrolate · 2020
- Saphnelo Anifrolumab-Fnia · 2026
- Wainua (Autoinjector) Eplontersen Sodium · 2023
- Beyfortus Nirsevimab-Alip · 2023
- Calquence Acalabrutinib · 2017
- Calquence Acalabrutinib Maleate · 2022
- Tezspire Tezepelumab-Ekko · 2021
- Airsupra Albuterol Sulfate, Budesonide · 2023
- Lynparza Olaparib · 2017
- Voydeya Danicopan · 2024
- Strensiq Asfotase Alfa · 2015
- Kanuma Sebelipase Alfa · 2015
- Lokelma Sodium Zirconium Cyclosilicate · 2018
- Nexium Esomeprazole Magnesium · 2008
- Nexium Esomeprazole Magnesium · 2001
- Nexium Esomeprazole Magnesium · 2006
- Imjudo Tremelimumab-Actl · 2022
- Prilosec Otc Omeprazole Magnesium · 2003
- Nexium 24hr Esomeprazole Magnesium · 2015
- Nexium 24hr Esomeprazole Magnesium · 2014
- Iressa Gefitinib · 2015
- Faslodex Fulvestrant · 2002
- Bevespi Aerosphere Formoterol Fumarate, Glycopyrrolate · 2016
- Pulmicort Respules Budesonide · 2000
- Daliresp Roflumilast · 2011
- Symbicort Budesonide, Formoterol Fumarate Dihydrate · 2006
- Casodex Bicalutamide · 2008
- Arimidex Anastrozole · 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.